Management of patients with demension: holinergic deficiency and its correction
https://doi.org/10.21518/2079-701X-2018-12-30-35
Abstract
The article discusses clinical symptoms, diagnostic criteria and basic principles of managing patients with dementia. It also provides the classification of cognitive disorders by severity degrees and considers the differences between the different degrees of dementia severity. The main features of the pathogenesis of cognitive disorders in dementia, the most important approaches to managing patients with dementia are highlighted. The article presents a detailed review of modern drugs used to correct cognitive and other manifestations of dementia.
About the Author
A. B. Lokshina
I.M. Sechenov First Moscow Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Yakhno NN. Cognitive disorders in the neurological clinic. Nevrol Zhurn, 2006, 11 (1): 4-12.
2. Yakhno NN, Zakharov VV, Lokshina AB, Koberskaya NN, Mkhitaryan EA. Dementia. A guide for doctors. Moscow: MedPress-Inform, 2011, 272 p.
3. Zakharov VV, Yakhno NN. Cognitive disorders in the elderly and senile age. A methodical guide for doctors. M., 2005. 71 p.
4. Damulin IV. Alzheimer’s disease and vascular dementia. Edited by Yakhno NN. M., 2002: 85 p.
5. Lokshina AB, Zakharov VV. Cognitive impairment in general clinical practice. Vrach, 2009, 4: 21-25.
6. Yakhno NN, Zakharov VV, Lokshina AB. Impaired memory and attention in the elderly. Zhurnal Nevrol. i psikhiatr. Im. S. S. Korsakova, 2006, 106 (2): 58-63.
7. Damulin IV, Yakhno NN. Degenerative diseases with cognitive disorders. In the book: Diseases of the nervous system. A guide for doctors. Edited by Yakhno N.N. M.: Medicine, 2005, Vol. 2: 192-207.
8. ICD-10. International Statistical Classification of Diseases and Health Related Problems, 10th revision. WHO, Geneva (M: Medicine by the Ministry of Health of the Russian Federation). 1995, T. 1: 320, 315, 317, 510-511.
9. Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Cognitive disorders. M., 2014, 192 p.
10. Davies P. The cholinergic deficit in Alzheimer’s disease. In: Alzheimer’s disease: 100 years and beyond. M. Jucker, K. Beyreuther, C. Haass (eds.). Springer-Verlag: Berlin, Heidelberg. 2006: 123-125.
11. Mendez M, Cummings J. Dementia: a clinical approach. Philadelphia: Elsevier Science. 2003: 179-234.
12. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev, 2006, (1): CD005593.
13. Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med, 2008, 148: 370-378.
14. Zakharov VV, Yakhno NN. Modern aspects of pharmacotherapy of dementia. Nevrol Zhurn, 2006, 2: 3-6.
15. Gavrilova SI, Kolykhalov IV, Kalyn YaB., Selezneva ND. Experience in using galantamine (reminil) for the treatment of Alzheimer’s disease at the stage of severe dementia. Zhurnal Nevrol. i Psikhiatr. Im. S. S. Korsakova, 2009, 109 (7): 57-61.
16. Lovenstone S, Gauthier S. Management of dementia. London: Martin Dunitz, 2001.
17. Wilcock GK, Bucks RS, Rockwood K. Diagnosis and management of dementia. A manual for memory disorders team. Oxford, N.Y.: Oxford University Press. 1999. P. 251.
18. Erkinjuntti T, Roman G, Gauthier S et al. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke, 2004, 35: 1010-1017.
19. Parfenov VA. Prevention and treatment of Alzheimer’s disease. Meditsinsky Sovet, 2014, 18: 20-26.
20. Gavrilova SI, Kalyn YaB, Selezneva ND. Glutamatergic therapy of Alzheimer’s disease at the stage of moderately severe and severe dementia: results of a 26-week study of the efficacy and safety of the drug akatinol memantine. Journal of Neuropathol. and a psychiatrist. them. S.S. Korsakov, 2005, 2: 72-76.
21. Kolykhalov IV, Gavrilova SI, Kalyn Ya.B., Selezneva ND, Fedorova YaB. A comparative clinical study of safety and tolerability of a single dose of akatinol memantine in comparison to two-doses in patients with moderately expressed and moderately severe dementia in Alzheimer’s disease. Zhurnal Nevrol. i psikhiatr. Im. S. S. Korsakova, 2012, 1: 35-39.
22. Yakhno NN, Preobrazhenskaya IS, Zakharov VV, Mkhitaryan EA. The efficacy of akatinol memantine in patients with non-cognitive impairments. Results of multicenter clinical observation. Neurol Journal, 2010, 15 (2): 52-58.
23. Uspenskaya OV, Yakhno NN. The effect of memantine on cognitive function in patients with amnestic moderate cognitive impairment syndrome (clinical-psychological and neurochemical study). Nevrol. Zhurnal, 2009, 14 (3): 49-54.
24. Yakhno NN, Preobrazhenskaya IS, Zakharov VV, Stepkina DA, Lokshina. AB, Mkhitaryan EA, Koberskaya NN, Savushkina IYu. The prevalence of cognitive impairment in neurological diseases (analysis of activities of specialized outpatient reception hours). Nevrologiya, Nejropsikhiatriya, Psikhosomatika 2012, 26: 30-35.
Review
For citations:
Lokshina AB. Management of patients with demension: holinergic deficiency and its correction. Meditsinskiy sovet = Medical Council. 2018;(12):30-35. (In Russ.) https://doi.org/10.21518/2079-701X-2018-12-30-35
Views:
802
Email this article 